intES selected for 1stRound non-equity support
The regenerative medicine startup is developing intestinal tissue sheets.
intES was named among the eight teams selected for the 15th 1stRound programme, announced on 5 October 2026. The programme provides non-equity funding and business development support; the company’s individual allocation was not disclosed.
The startup is working on embryonic stem cell-derived intestinal tissue for inflammatory bowel disease. Technical adviser Akihiro Umezawa brings expertise in the manufacturing, safety and regulatory work needed to translate cell therapies into clinical practice.
Use of funds
ES-cell-derived intestinal tissue development and business support